{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:55:32Z","timestamp":1790625332578,"version":"4.1.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Malignancies in infants younger than 6 months differ from those in older children in incidence, clinical presentation, treatment response, and outcomes. Limited data exist on these infants\u2019 survival, particularly in low- and middle-income countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Procedure:<\/jats:title>\n                    <jats:p>We retrospectively analyzed the data of 153 infants (&lt;6\u00a0mo) with diagnosed retinoblastoma (n=116), neuroblastoma (n=20), or leukemia (n=17) at MAHAK Pediatric Cancer Treatment and Research Center (2007 to 2021). Demographics, disease characteristics, family history, treatment, and survival outcomes were collected. Overall survival (OS) was estimated by using the Kaplan-Meier method, and prognostic factors were evaluated using the Mantel-Cox log-rank testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Retinoblastoma was the most common diagnosis, with 67.8% of retinoblastoma cases being bilateral. Various stages and subtypes of neuroblastoma and leukemia were present. Family history of cancer was positive in 53.8% of patients. Most patients with neuroblastoma or retinoblastoma experienced remission; however, those with leukemia experienced high mortality (14\/17). Diagnosis significantly predicted survival (RR for leukemia: 4, 95% CI: 0.43-4.19,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001). Thus, the 5-year OS rate was 79.1% overall but was 14.7% for leukemia, 86% for retinoblastoma, and 100% for neuroblastoma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Infants younger than 6 months with leukemia, retinoblastoma, or neuroblastoma show distinct clinical patterns and have differing survival rates. Neuroblastoma and retinoblastoma have favorable outcomes, whereas leukemia carries a poor prognosis. Early recognition, tailored therapy, and follow-up are essential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mph.0000000000003268","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:00:37Z","timestamp":1787929237000},"page":"e339-e344","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and Epidemiological Characteristics of Infants &lt;6 Months With Leukemia, Neuroblastoma, and Retinoblastoma in a Single Center in Iran"],"prefix":"10.1097","volume":"48","author":[{"given":"Mohammad","family":"Faranoush","sequence":"first","affiliation":[{"name":"MAHAK Hematology Oncology Research Center (MAHAK-HORC), MAHAK Hospital, Shahid Beheshti University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Qaddoumi","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azim","family":"Mehrvar","sequence":"additional","affiliation":[{"name":"Pediatric Hematology-Oncology, Parvaneh Childhood Cancer Center, Golestan Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Musakhani","sequence":"additional","affiliation":[{"name":"MAHAK Hematology Oncology Research Center (MAHAK-HORC), MAHAK Hospital, Shahid Beheshti University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Ashrafi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, School of Medicine, Iran University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narjes","family":"Mehrvar","sequence":"additional","affiliation":[{"name":"Pediatric Hematology-Oncology, Parvaneh Childhood Cancer Center, Golestan Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithra","family":"Ghalibafian","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, MAHAK Pediatric Cancer Treatment and Research Center, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0886-3233","authenticated-orcid":false,"given":"Mahyar","family":"Nourian","sequence":"additional","affiliation":[{"name":"MAHAK Hematology Oncology Research Center (MAHAK-HORC), MAHAK Hospital, Shahid Beheshti University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"R1-20260928","doi-asserted-by":"crossref","first-page":"101697","DOI":"10.1016\/j.canep.2020.101697","article-title":"Infant cancers in France: incidence and survival (2000\u20132014)","volume":"65","author":"Desandes","year":"2020","journal-title":"Cancer epidemiology"},{"key":"R2-20260928","doi-asserted-by":"crossref","first-page":"e0130444","DOI":"10.1371\/journal.pone.0130444","article-title":"Infant cancer in Taiwan: incidence and trends (1995-2009)","volume":"10","author":"Hung","year":"2015","journal-title":"PLoS ONE"},{"key":"R3-20260928","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/CEJ.0b013e32833876c0","article-title":"Incidence of childhood cancer in France","volume":"19","author":"Lacour","year":"2010","journal-title":"Eur J Cancer Prev"},{"key":"R4-20260928","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1745-7599.2010.00503.x","article-title":"Neuroblastoma: what the nurse practitioner should know","volume":"22","author":"Mazur","year":"2010","journal-title":"J Am Acad Nurse Pract"},{"key":"R7-20260928","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1177\/0883073811401398","article-title":"Characterization, treatment, and outcome of intracranial neoplasms in the first 120 days of life","volume":"26","author":"Qaddoumi","year":"2011","journal-title":"J Child Neurol"},{"key":"R8-20260928","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1002\/cam4.1122","article-title":"Neonates with cancer and causes of death; lessons from 615 cases in the SEER databases","volume":"6","author":"Alfaar","year":"2017","journal-title":"Cancer Med"},{"key":"R9-20260928","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11060-018-03048-0","article-title":"Neuropsychological outcomes of patients with low-grade glioma diagnosed during the first year of life","volume":"141","author":"Heitzer","year":"2019","journal-title":"J Neurooncol"},{"key":"R10-20260928","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/cncr.31918","article-title":"Treatment burden and long-term health deficits of patients with low-grade gliomas or glioneuronal tumors diagnosed during the first year of life","volume":"125","author":"Liu","year":"2019","journal-title":"Cancer"},{"key":"R11-20260928","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1891\/0730-0832.32.1.34","article-title":"Column title: malignancies and tumors in the neonate","volume":"32","author":"Mettling","year":"2013","journal-title":"Neonatal Netw"},{"key":"R12-20260928","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","article-title":"A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial","volume":"370","author":"Pieters","year":"2007","journal-title":"Lancet"},{"key":"R14-20260928","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/pbc.25501","article-title":"SIOP-PODC adapted risk stratification and treatment guidelines: recommendations for neuroblastoma in low-and middle-income settings","volume":"62","author":"Parikh","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"R15-20260928","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/sj.bjc.6601154","article-title":"Treatment of stage 4s neuroblastoma\u2013report of 10 years\u2019 experience of the French Society of Paediatric Oncology (SFOP)","volume":"89","author":"Schleiermacher","year":"2003","journal-title":"Br J Cancer"},{"key":"R16-20260928","doi-asserted-by":"crossref","first-page":"e28754","DOI":"10.1002\/pbc.28754","article-title":"Epidemiology and survival of childhood cancer in Turkey","volume":"68","author":"Kebudi","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"R17-20260928","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/leu.2011.267","article-title":"Favorable outcome in infants with AML after intensive first-and second-line treatment: an AML-BFM study group report","volume":"26","author":"Creutzig","year":"2012","journal-title":"Leukemia"},{"key":"R18-20260928","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.3390\/ijms25073721","article-title":"Infant acute lymphoblastic leukemia\u2014new therapeutic opportunities","volume":"25","author":"Kulczycka","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R19-20260928","doi-asserted-by":"crossref","first-page":"e1128","DOI":"10.1016\/S2214-109X(22)00250-9","article-title":"The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries","volume":"10","author":"Fabian","year":"2022","journal-title":"Lancet Glob Health"},{"key":"R20-20260928","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41433-021-01845-y","article-title":"Retinoblastoma and vision","volume":"37","author":"Warda","year":"2023","journal-title":"Eye"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000003268","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:00:30Z","timestamp":1790622030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000003268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003268","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"2025-12-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}